George Cardoza will be joining AccuraGen as its Chief Executive Officer and will also be joining the Board of Directors.
Several experts highly recognized AccuraGen's scientific research on early cancer detection.
Kang Ying, CEO of AccuraGen Holdings participated in NGS roundtable forum and shared his perspectives on cancer screening.
AccuraGen China passed the proficiency test of 2019-nCoV nucleic acid testing (NCCL)
AccuraGen unveil edits result of the collaborative research on the early detection of colorectal cancer at AGBT this year.
Shanghai Yunsheng Medical Laboratory hasactively participated in the 2019-nCoV nucleic acid detection capabilityverification organized by SCCL.
Shanghai Yunsheng Medical Laboratory participated in the campaign against 2019-nCoV on February 2nd.
Dr. Tao Fu presented new data as a poster at the ESMO 2019 Congress.
Several Collaborator Presented Research Result of Different Cancers
Research result conducted by Professor Jiatao Lou recently published on Small Methods.
AccuraGen sponsored the session of "Writing and Publication of English Papers on Pathology" at the 8th Annual Meeting of Chinese Pathologists.
The NGS laboratory under AccuraGen Holdings passed the NGSST Proficiency Testing assessment launched by CAP with full marks again.
Shanghai Yunsheng Medical Laboratory under AccuraGen Holdings participated in the launch of the Inclusive Medical Association.
The study was conducted by Professor Jiatao Lou, director of the Chest Hospital.
The High-throughput Sequencing (NGS) Laboratory of AccuraGen Holdings Group has been accredited by the College of American Pathologists (CAP).
Shanghai Yunsheng Medical Laboratory Co., Ltd., a subsidiary of AccuraGen Holdings, passed the external quality evaluation with 100 marks.
The Precision Medicine World Conference (PMWC) of 2018 was held in Silicon Valley from January 22 to 24 in the United States.
We have been understanding our health through a number of blood tests in a large spectrum of scenarios; ranging from diabetes to heart attack, from pregnancy to cancer. We track proteins, circulating DNA, miRNA, etc
With the advancement of technology, we can now capture and digitize analytes in our blood quantitatively. Firefly is the technology we built with many years of efforts to accurately convert signals from circulating tumor DNA to infer tumor load of an individual.
By gathering multi-omics information from a large population of healthy and cancer cohort, we train with the state-of-the-art machine learning algorithm to differentiate cancer and healthy status of an individual.
The potential applications of liquid biopsy are vast - from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening - and we believe it will play a critical role in the future of cancer management. With more clinical studies that we're collecting, we will show clincal utility for different applications. For the next person coming to our clinic, we will take a snapshot with his blood and try to catch cancer in a stage that can be treated.